Pasha 105: Two academics weigh in on Botswana allowing elephant hunting
The Conversation
29 Apr 2021, 04:44 GMT+10
Botswana recently offered the rights to shoot around 300 elephants. There have been mixed feelings about this decision. Some say licensed hunting is ecologically necessary. They also say rural communities need revenue from hunting and are at risk of human-wildlife conflict. Others have criticised it heavily, disputing the claim that hunting is a solution to various problems and pointing to its negative consequences.
Botswana is home to about one third of Africa s elephants and the numbers have increased over the years. The International Union for the Conservation of Nature has categorised savanna elephants as endangered, but they can be hunted if the decision to allow it is backed by scientific evidence.
Pasha 105: Two academics weigh in on Botswana allowing elephant hunting
modernghana.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernghana.com Daily Mail and Mail on Sunday newspapers.
Pasha 105: Two academics weigh in on Botswana allowing elephant hunting
theconversation.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theconversation.com Daily Mail and Mail on Sunday newspapers.
Last month marked a watershed in global efforts to fight the Covid-19 pandemic. US pharmaceutical company Pfizer and its German partner BioNTech announced that they had successfully developed a Covid-19 vaccine that has a 95% efficacy rate (the highest success rate thus far).
The vaccine has passed a late-stage clinical trial and the company has the capacity to produce more than 1 billion doses by 2021. This announcement ignited hope across a world that has been devastated by Covid-19 since it was first discovered in Wuhan, China, in late 2019.
Moderna, another US firm, reported earlier in the same month that its vaccine candidate has a 94% efficacy rate. Russia’s Sputnik V was the first vaccine to show an efficacy rate of more than 90%, having reported a 92% success rate on 11 November for the interim trial results. The UK’s Oxford-AstraZeneca vaccine has an efficacy rate of more than 70%, with capacity to produce around 3 billion doses by 2021.